Vinge Logotype
Svenska English 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises Impilo on the establishment of Impilo Healthcare
Mandate

Vinge advises Impilo on the establishment of Impilo Healthcare

July 01, 2025 Private Funds

Vinge has advised Impilo with regulatory advice on the establishment of Impilo Healthcare. The fund will have EUR 320m in commitments.

Impilo is a Nordic investment company focused solely on investments in lower-mid market Nordic healthcare companies across the pharmaceuticals, MedTech, specialist pharma services and other healthcare and related services industries. Impilo has a well-diversified portfolio of healthcare investments and manages approximately EUR 2 billion of capital from leading international investors.

Vinges team consisted of Nils Unckel, Anton Sjökvist, Viktoria Wnuk and Isabelle Asserståhl.

Related

Vinge advises Cantargia in connection with the sale of immunology program CAN10

 Vinge advises Cantargia AB (publ) in connection with the sale of its early-clinical stage IL1RAP immunology program CAN10 to the Japanese healthcare company Otsuka Pharmaceutical.
July 21, 2025

Vinge has assisted PulPac in connection with it obtaining a €20 million financing from the European Investment Bank

 Vinge has assisted Gothenburg-based sustainable packaging technology company PulPac in connection with it obtaining a €20 million (around 220 million Swedish kronor) financing from the European Investment Bank (EIB).
July 18, 2025

Vinge has advised Behold Ventures in the fundraising of Behold Ventures’ first-time fund

Behold Ventures held its final closing on 27 June 2025, thereby securing investor commitments to its first-time fund amounting to approximately SEK 550 million from an international investor base, comprising the European Investment Fund (EIF), among others.
July 10, 2025